A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data
A Prospective Registry for Collecting Standardized, Routine Care Data to Characterize Patients, Treatment Patterns, Safety and Treatment Effectiveness in Adult Oncology Patients
1 other identifier
observational
20,000
1 country
7
Brief Summary
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2022
Longer than P75 for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2022
CompletedFirst Submitted
Initial submission to the registry
February 11, 2025
CompletedFirst Posted
Study publicly available on registry
March 14, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2099
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2099
October 20, 2025
October 1, 2025
76.5 years
February 11, 2025
October 16, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Treatment Effectiveness - Time to treatment discontinuation
Effectiveness outcomes of treatments used in routine clinical care (such as for instance time to treatment discontinuation ) will be captured
This is an open-ended registry where data will be collected, analysed and presented regularly over time.
Eligibility Criteria
All patients at oncology sites participating in the registry.
You may qualify if:
- Be a patient at a site (oncology) participating in the Registry Be at least 18 years old Be able and willing to provide signed informed consent
You may not qualify if:
- Prisoners/imprisonment at time of screening for eligibility Patients who cannot consent without utilization of a legally authorized representative
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- N-Power Medicinelead
Study Sites (7)
Pacific Cancer Care
Monterey, California, 93940, United States
Bayhealth Cancer Center-Kent
Dover, Delaware, 19901, United States
Bayhealth Cancer Center- Sussex
Milford, Delaware, 19963, United States
Northwest Oncology & Hematology
Elk Grove Village, Illinois, 60007, United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109, United States
Lankenau Medical Center
Paoli, Pennsylvania, 19301, United States
Oncology Consultants, P.A.
Houston, Texas, 77030, United States
MeSH Terms
Conditions
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 11, 2025
First Posted
March 14, 2025
Study Start
August 1, 2022
Primary Completion (Estimated)
January 1, 2099
Study Completion (Estimated)
January 1, 2099
Last Updated
October 20, 2025
Record last verified: 2025-10